Quick answers
- What is Meropenem-vaborbactam used for?
- The FDA-approved label (Vabomere, Melinta Therapeutics, LLC, February 27, 2026) says: “VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Meropenem-vaborbactam have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Meropenem-vaborbactam?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Meropenem-vaborbactam been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Meropenem-vaborbactam?
- 1 company lists prescription products of Meropenem-vaborbactam in the FDA NDC Directory, including Melinta Therapeutics, LLC.
What Meropenem-vaborbactam is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. …
— FDA label: Vabomere, Melinta Therapeutics, LLC, effective February 27, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, for solution |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Vabomere |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Melinta Therapeutics, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA209776 VABOMERE | Rempex | August 29, 2017 | 5, latest February 20, 2026 2026: Labeling · 2024: Labeling · 2023: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1945218, 1946651 |
|---|---|
| SPL set ID of the quoted label | e237fd0f-3050-42a3-b43e-b6fb4824e93d |
| FDA labels (SPL) | 1 |
| FDA applications | NDA209776 |
| Active ingredients (FDA) | MEROPENEM / VABORBACTAM |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Vabomere, Melinta Therapeutics, LLC, effective February 27, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →